Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817310 | 0.93 | CYP2A6 (0.49) | FLT1CYP1A2CYP2D6CHRNA7GPR84 | |
| SCHEMBL5332250 | 0.86 | FLT1 (0.62) | FLT1CYP1A2CYP2D6HRH4HRH3 | |
| SCHEMBL4818505 | 0.79 | GAA (0.43) | FLT1GAAHRH1MAPT | |
| SCHEMBL5753555 | 0.78 | FLT1 (0.80) | FLT1 | |
| SCHEMBL14267794 | 0.76 | FLT1 (0.65) | FLT1CYP1A2 | |
| SCHEMBL29981747 | 0.76 | CYP1A2 (0.46) | CYP1A2CYP2D6CHRNA7GPR84CYP2A6 | |
| SCHEMBL4828189 | 0.76 | HTR1A (0.50) | CYP1A2CYP2D6CHRNA7GPR84CYP2A6 | |
| SCHEMBL7569609 | 0.76 | CYP1A2 (0.46) | CYP1A2CYP2D6CHRNA7GPR84CYP2A6 | |
| SCHEMBL5753111 | 0.75 | KMT2A (0.52) | FLT1GAAMAPT | |
| SCHEMBL724866 | 0.74 | CHRNA7 (0.74) | CYP1A2CYP2D6CHRNA7CYP2A6HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO | 2006-09-28 | — | — | US | disclosed |
| EP-1165085-B1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| CN-1221262-C | Phthalazine derivatives for the treatment of inflammatory diseases | NOVARTIS AG (CH) | 2005-10-05 | — | — | CN | disclosed |
| CN-1660840-A | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-08-31 | — | — | CN | disclosed |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6911440-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-06-28 | — | — | US | disclosed |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2004-07-22 | — | — | US | disclosed |
| US-6686347-B2 | RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS | NOVARTIS AG (CH) | 2004-02-03 | — | — | US | disclosed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | disclosed |
| CN-1367695-A | Phthalazine derivatives for the treatment of inflammatory diseases | NOVARTIS AG (CH) | 2002-09-04 | — | — | CN | disclosed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | FLT1 1/4885CYP1A2 931/4885CYP2D6 2060/4885 |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, NR2E3, FLT1 | FLT1 3/4885CYP1A2 2795/4885CYP2D6 4187/4885 |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, FLT1, TIE1 | FLT1 2/4885CYP1A2 2708/4885CYP2D6 3973/4885 |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, FLT4, KDR | FLT1 1/4885CYP1A2 695/4885CYP2D6 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.